To investigate the effect of neoadjuvant chemotherapy on tumor shrinkage, we assessed the correlation between NK cell surface activation markers, such as TRAIL, NKp30, NKp46, NKG2D, CD122, and SIRPβ, in PBMC and LMNC and the chemotherapy response clinically evaluated using RECIST or the histological treatment response (grade classification) were studied in patients receiving neoadjuvant chemotherapy followed by hepatectomy. The gene discussed is KLRK1; the disease is neoplasm.